Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $115.00 Price Target at Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target lifted by Chardan Capital from $90.00 to $115.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock.

A number of other analysts also recently commented on ARWR. JPMorgan Chase & Co. boosted their price target on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Weiss Ratings lowered shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 1st. Finally, Sanford C. Bernstein boosted their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $90.83.

Arrowhead Pharmaceuticals Stock Performance

ARWR stock opened at $88.70 on Wednesday. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. The firm has a market cap of $12.49 billion, a P/E ratio of -41.26 and a beta of 1.26. Arrowhead Pharmaceuticals has a 12-month low of $15.01 and a 12-month high of $95.49. The stock’s 50 day simple moving average is $77.62 and its 200 day simple moving average is $69.73.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. The firm had revenue of $73.74 million for the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm’s revenue for the quarter was down 86.4% on a year-over-year basis. During the same period last year, the business posted $2.75 earnings per share. As a group, equities research analysts predict that Arrowhead Pharmaceuticals will post -3.09 EPS for the current year.

Insider Activity

In related news, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares in the company, valued at approximately $3,998,682.56. This trade represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Carolina Wealth Advisors LLC grew its stake in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares in the last quarter. CWM LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 1.4% during the 4th quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock valued at $820,000 after buying an additional 168 shares during the last quarter. First Horizon Corp grew its stake in shares of Arrowhead Pharmaceuticals by 36.2% in the 1st quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 174 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Arrowhead Pharmaceuticals by 1.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock worth $737,000 after buying an additional 178 shares during the last quarter. Finally, Optiver Holding B.V. raised its position in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 186 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Key Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported positive topline Phase 3 results for plozasiran in severe hypertriglyceridemia, supporting a potential regulatory submission later this year and strengthening the drug’s commercial outlook. Article: Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
• Positive Sentiment: Chardan Capital raised its price target on Arrowhead Pharmaceuticals from $90 to $115 and reiterated a buy rating, signaling increased analyst confidence after the trial data. Article: Read More
• Positive Sentiment: Market commentary highlights Arrowhead’s plozasiran data as a potential breakthrough that could help the company gain share in the lipid-disorder market and challenge Ionis, which adds to bullish sentiment. Article: Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug
• Neutral Sentiment: The company also announced an upcoming webcast for fiscal Q3 2026 results on August 4, which is routine investor communication and not a major immediate catalyst. Article: Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
• Neutral Sentiment: One note said the stock may look expensive after a large run, but that is more of a valuation check than a direct negative catalyst. Article: Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.